Octagon Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Out of Business

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Out of Business

Octagon Therapeutics General Information

Description

Developer of targeted immunomodulator medicines intended to reset immune homeostasis in patients with chronic autoimmune and inflammatory disease. The company's medicines pioneer a selective immunomodulation approach based on glycol-immune checkpoint receptors that precisely target disease-driving immune processes, enabling patients to avoid chronic immunosuppression by selectively targeting dysregulated immune cells.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Dyer Street
  • Providence, RI 02903
  • United States
+1 (857)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 225 Dyer Street
  • Providence, RI 02903
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Octagon Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Out of Business 29-Apr-2025 Completed Out of Business
10. Later Stage VC 12-Feb-2024 Completed Pre-Clinical Trials
9. Later Stage VC 01-Jan-2023 Completed Pre-Clinical Trials
8. Seed Round 01-Dec-2022 Completed Pre-Clinical Trials
7. Accelerator/Incubator 01-Oct-2022 Completed Pre-Clinical Trials
6. Seed Round 17-Nov-2021 Completed Pre-Clinical Trials
5. Accelerator/Incubator 18-Oct-2019 Completed Pre-Clinical Trials
4. Seed Round 15-Feb-2018 Completed Pre-Clinical Trials
3. Accelerator/Incubator 23-Aug-2017 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jun-2017 Completed Pre-Clinical Trials
To view Octagon Therapeutics’s complete valuation and funding history, request access »

Octagon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-1
Seed-2
To view Octagon Therapeutics’s complete cap table history, request access »

Octagon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted immunomodulator medicines intended to reset immune homeostasis in patients with chronic autoimmune
Drug Discovery
Providence, RI
14 As of 2025

Zwijnaarde, Belgium
 

Warsaw, Poland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Octagon Therapeutics Competitors (5)

One of Octagon Therapeutics’s 5 competitors is Argenx, a Formerly VC-backed company based in Zwijnaarde, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Argenx Formerly VC-backed Zwijnaarde, Belgium
Ucb Pharma (Poland) Corporation Warsaw, Poland
AbbVie Corporation North Chicago, IL
Novartis Corporation Basel, Switzerland
Sanofi Corporation Gentilly, France
You’re viewing 5 of 5 competitors. Get the full list »

Octagon Therapeutics Patents

Octagon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024192243-A2 Binding agents for treatment of autoimmune conditions Inactive 15-Mar-2023
WO-2024192243-A3 Binding agents for treatment of autoimmune conditions Inactive 15-Mar-2023
WO-2024158832-A2 Detection and treatment of immune conditions Inactive 23-Jan-2023
WO-2024158832-A3 Detection and treatment of immune conditions Inactive 23-Jan-2023
US-20240350649-A1 Treatment and diagnosis of immune disorders relating to aberrant immune cells Pending 05-Aug-2021 A61K47/68
To view Octagon Therapeutics’s complete patent history, request access »

Octagon Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Octagon Therapeutics FAQs

  • When was Octagon Therapeutics founded?

    Octagon Therapeutics was founded in 2016.

  • Where is Octagon Therapeutics headquartered?

    Octagon Therapeutics is headquartered in Providence, RI.

  • What is the size of Octagon Therapeutics?

    Octagon Therapeutics has 14 total employees.

  • What industry is Octagon Therapeutics in?

    Octagon Therapeutics’s primary industry is Drug Discovery.

  • Is Octagon Therapeutics a private or public company?

    Octagon Therapeutics is a Private company.

  • What is Octagon Therapeutics’s current revenue?

    The current revenue for Octagon Therapeutics is .

  • How much funding has Octagon Therapeutics raised over time?

    Octagon Therapeutics has raised $14M.

  • Who are Octagon Therapeutics’s competitors?

    Argenx, Ucb Pharma (Poland), AbbVie, Novartis, and Sanofi are competitors of Octagon Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process